Lantheus Holdings, Inc. (LNTH) Stock Price & Analysis
Lantheus Holdings, Inc. (LNTH) fell 0.03% to USD 99.98 as of June 10, 2026 at 03:34 UTC, according to Nexqual real-time market data.
LNTH last closed at USD 100.01; the session ranged USD 97.99–101.81 on volume of 645,900 shares. Market capitalization is $6.51B, with a 52-week range of USD 47.25–104 (NGM). Source: Nexqual, June 10, 2026 at 03:34 UTC.
Key Statistics (as of June 10, 2026 at 03:34 UTC)
| Price | USD 99.98 |
|---|---|
| Change | ▼ 0.03% (down) |
| Previous Close | USD 100.01 |
| Open | USD 100.92 |
| Day Range | USD 97.99 – 101.81 |
| 52-Week Range | USD 47.25 – 104 |
| Volume | 645,900 shares |
| Market Cap | $6.51B |
| Exchange | NGM |
Technical Analysis (LNTH)
Nexqual's technical model rates LNTH "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 03:34 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.66 (neutral) |
| vs SMA50 | Above (USD 88.87) |
| MACD | 3.32 (positive) |
Analyst Ratings (LNTH)
Wall Street analysts rate LNTH "Strong Buy" based on 13 analysts, with a mean price target of USD 105.23 (range USD 76–117), per Nexqual as of June 10, 2026 at 03:34 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 105.23 |
| High Target | USD 117 |
| Low Target | USD 76 |
| Buy / Hold / Sell | 11 / 2 / 0 |
Earnings (LNTH)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 1.3 |
| Revenue Estimate | $363.22M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.46 vs est 1.23 ▲ beat |
| 2025-12-31 | USD 1.67 vs est 1.17 ▲ beat |
| 2025-09-30 | USD 1.27 vs est 1.27 ▲ beat |
| 2025-06-30 | USD 1.57 vs est 1.68 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:34 UTC.
Financials & Fundamentals (LNTH)
| Total Revenue | $1.55B |
|---|---|
| Revenue Growth (YoY) | +1.20% |
| Gross Margin | +60.48% |
| Operating Margin | +21.65% |
| Profit Margin | +18.05% |
| ROE | +23.48% |
| Debt / Equity | 51.62 |
| Current Ratio | 2.83 |
| Total Cash | $498.58M |
| Total Debt | $625.75M |
| Free Cash Flow | $421.71M |
Source: Nexqual, June 10, 2026 at 03:34 UTC.
Financial Health Score (LNTH)
Nexqual rates Lantheus Holdings, Inc.'s overall financial health "Strong" across five dimensions, as of June 10, 2026 at 03:34 UTC.
| Growth | Mixed — Revenue +0.5% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 60%, operating 22% |
| Balance Sheet | Strong — $499M cash vs $626M debt |
| Cash Flow | Strong — FCF $422M, 27% margin |
| Efficiency | Strong — ROE 23%, ROA 8.2% |
Ownership (LNTH)
| Insider Ownership | +2.09% |
|---|---|
| Institutional Ownership | +115.60% |
| Shares Outstanding | 65.11M |
| Float | 58.36M |
| Short % of Float | +11.20% |
Source: Nexqual, June 10, 2026 at 03:34 UTC.
Leadership (LNTH)
Lantheus Holdings, Inc. is led by Mary Anne Heino (age 65), Interim CEO & Executive Chairperson, per Nexqual as of June 10, 2026 at 03:34 UTC.
| Interim CEO & Executive Chairperson | Mary Anne Heino (age 65) |
|---|---|
| CFO & Treasurer | Robert J. Marshall Jr. (age 58) |
| Vice President of Business Insights & Operations | Neil Holland |
| Senior Vice President of Manufacturing & Technical Operations | Dorothy Barr |
Major Backers & Investors (LNTH)
Notable institutional backers of Lantheus Holdings, Inc. include Farallon Capital Management LLC, Janus Henderson Group PLC, FMR, LLC, according to Nexqual as of June 10, 2026 at 03:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Farallon Capital Management LLC | 8.58% |
| Janus Henderson Group PLC | 7.33% |
| FMR, LLC | 7.11% |
| American Century Companies Inc | 5.27% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 3.12% |
| Morgan Stanley | 2.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.37% |
| Vanguard Group | 17.22% |
| State Street | 3.73% |
| Geode Capital | 2.71% |
Source: Nexqual, June 10, 2026 at 03:34 UTC.
From Lantheus Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
- It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart.
- In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent.
- It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MEDP | Medpace Holdings, Inc. | USD 466.79 | ▲ 2.76% |
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
| KRYS | Krystal Biotech, Inc. | USD 309.75 | ▲ 2.91% |
| NTRA | Natera, Inc. | USD 222.82 | ▲ 3.49% |
| AMPH | Amphastar Pharmaceuticals, Inc. | USD 20.16 | ▲ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:34 UTC. This page is informational and not investment advice.